| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2359649-81-1 | [Synonyms]
Enbezotinib
(13E,14E,15aR,18aS,5S)-35-fluoro-5-methyl-15,15a,16,17,18,18a-hexahydro-4-oxa-7-aza-1(5,3)-cyclopenta[b]pyrazolo[1',5':1,2]pyrimido[4,5-e][1,4]oxazina-3(3,2)-pyridinacyclooctaphan-8-one
17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aR,11S,20aS)- | [Molecular Formula]
C21H21FN6O3 | [MOL File]
2359649-81-1.mol | [Molecular Weight]
424.43 |
| Chemical Properties | Back Directory | [density ]
1.68±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (235.61 mM; ultrasonic and warming and heat to 80°C) | [form ]
Solid | [pka]
10.44±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer[1]. | [in vivo]
Enbezotinib (compound 5) (2-5 mg/kg; twice daily for 27 days) decreases tumor size in mice[1]. | [References]
[1] ROGERS EW, et, al. Macrocyclic compounds for treating disease. WO2019126121A1. |
| Spectrum Detail | Back Directory | [Spectrum Detail]
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?-(2359649-81-1)1HNMR
|
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|